Stocks · News reference
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.47) by 19.57 percent. This is a 16.67 percent increase over losses of $(0.66) per share
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-27 AccNo: 0001708599-26-000051 Size: 254 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Read original at edgar-SEC Filing
Read original at benzinga- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in
Read original at benzinga